BE-101, soon to be known as Optavant, is expected to be commercially available in the third quarter of this year after it receives full licensure from the U.S. Department of Agriculture.
The organization has already raised $3.9 million for its campaign with gifts from Eli Lilly and Co. Foundation, United Way of Central Indiana and other groups.
Trial patients who received the drug after surgery or radiation therapy experienced an 83% reduction in the risk of disease recurrence or death compared with those who received a placebo.
The travel center will feature a convenience store, gift shop, extensive food offerings and bathrooms, plus gas pumps and electric vehicle charging stations.
After transforming the treatment of diabetes and weight loss, a growing body of research is raising the possibility that these drugs may help protect against cancer.
If fulfilled, the proposed agreements signal an end for some potential legal roadblocks to the development of the Citizens-Lebanon Water Supply Program.
